Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lance Berger

Cardiovascular Disease Toms River, NJ Medical Doctor

NPI 1689679490 CMS profile 122052

780 Route 37 W Ste 310, Toms River, NJ 08755

Open in the dashboard

General payments

$11,888

162 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$120,098 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Lance Berger of Toms River, NJ is reported in the CMS Open Payments database as having received $11,888 across 162 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $120,098 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $910 49
2024 General $5,864 36
2023 General $1,452 18
2022 General $1,429 11
2021 General $413 14
2020 General $68 3
2019 General $1,752 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lance Berger
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Lance Berger were reported at $910. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Lance Berger Cardiovascular Disease median Middle half National median
2019 $1,752 $450 $127–$1,392 $163
2020 $68 $242 $77–$751 $114
2021 $413 $335 $101–$1,037 $132
2022 $1,429 $395 $121–$1,211 $149
2023 $1,452 $443 $136–$1,283 $160
2024 $5,864 $450 $136–$1,323 $164
2025 $910 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $6,146 31 payments
  2. Abbott Laboratories $1,394 13 payments
  3. Novartis Pharmaceuticals Corporation $1,325 10 payments
  4. AstraZeneca Pharmaceuticals LP $748 15 payments
  5. E.R. Squibb & Sons, L.L.C. $705 28 payments
  6. Boston Scientific Corporation $464 10 payments
  7. Alnylam Pharmaceuticals Inc. $287 16 payments
  8. Daiichi Sankyo Inc. $129 2 payments
  9. Janssen Pharmaceuticals, Inc $106 7 payments
  10. iRhythm Technologies, Inc. $100 3 payments
  11. Other $485 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,600 1 payment
  2. Food and Beverage $4,090 150 payments
  3. Travel and Lodging $1,992 9 payments
  4. Consulting Fee $1,188 1 payment
  5. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. VYNDAQEL $6,036 24 payments
  2. Mitra Clip system $1,286 7 payments
  3. LEQVIO $1,188 1 payment
  4. CAMZYOS $407 20 payments
  5. WAINUA $362 3 payments
  6. FARXIGA $321 7 payments
  7. RESONATE $226 2 payments
  8. WATCHMAN $164 5 payments
  9. AMVUTTRA $146 4 payments
  10. ONPATTRO $141 12 payments
  11. Other $1,624 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,962

Median for Cardiology: 2,533

Drug cost

$1,129,781

Median for Cardiology: $485,213

Branded share of claims

24.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 15 $487,898
Eliquis Apixaban Brand 238 $279,010
Entresto Sacubitril/Valsartan Brand 95 $113,408
Xarelto Rivaroxaban Brand 54 $59,980
Farxiga Dapagliflozin Propanediol Brand 68 $56,007
Repatha Sureclick Evolocumab Brand 47 $47,456
Brilinta Ticagrelor Brand 18 $19,829
Jardiance Empagliflozin Brand 15 $10,233
Icosapent Ethyl Generic 15 $8,613
Rosuvastatin Calcium Generic 385 $6,336

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$109,024

Medicare's payments for the services billed

Medicare patients

566

Average age 76

Services billed

1,991

283 women, 283 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Arthritis 54%
Diabetes 42%
Atrial fibrillation 34%
Chronic kidney disease 33%
Heart failure 29%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $4,833
$4,833 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $238
$238 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $149
$149 68 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $146
$146 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record